Skip to content
DataLookout
Start free
Menu

Also listed under Autoimmune Diseases of the Nervous System, Neuromuscular Junction Diseases

Myasthenia Gravis clinical trials

Get alerts when Myasthenia Gravis trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14

What changed in the last 30 days

22 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 17 with minor changes only.

  1. Minor: IMVT-1402 · Mild to Severe Generalized Myasthenia Gravis Trial sites expanded: 88 → 93 locations Immunovant Sciences GmbHPhase 3 NCT07039916
  2. Minor: Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Jagiellonian UniversityNot specified NCT05337891
  3. Minor: Whole-body Electrical Muscle Stimulation Exercise on · Neuromuscular Disease Enrollment closed, study ongoing University of Missouri-ColumbiaNot applicable NCT07478172
  4. Minor: MyVisionXT · Rozanolixizumab · Ocular Myasthenia Gravis Trial sites expanded: 7 → 18 locations UCB Biopharma SRLPhase 3 NCT07465289
  5. Minor: MyVision · Rozanolixizumab · Ocular Myasthenia Gravis Trial sites expanded: 29 → 36 locations UCB Biopharma SRLPhase 3 NCT07463521
  6. Notable: HARMONY 360 · Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360 Primary and study completion pushed from Oct 2027 to Oct 2028 Ad scientiamNot applicable NCT07323316
  7. Minor: ziMyG · Subcutaneous Zilucoplan · Generalized Myasthenia Gravis Primary completion pushed from Nov 16, 2026 to May 12, 2027 UCB Biopharma SRLPhase 2/3 NCT06055959
  8. Minor: ADAPT Forward2 · ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 8 → 14 locations argenxPhase 2 NCT07673627
  9. Minor: EPIC · Comparative Efficacy of Nipocalimab and Efgartigimod · Generalized Myasthenia Gravis Trial sites expanded: 19 → 31 locations Janssen Research & Development, LLCPhase 3 NCT07217587
  10. Notable: Maintenance Ublituximab Following Induction With Efgartigimod Administration · Myasthenia Gravis (MG) Start date pushed from Oct 1, 2026 to Nov 1, 2026 TG Therapeutics, Inc.Phase 2 NCT07673744
  11. Minor: ADAPT Jr · Efgartigimod Administered Intravenously · Generalized Myasthenia Gravis Enrollment closed, study ongoing argenxPhase 2/3 NCT04833894
  12. Minor: Rozanolixizumab · Generalized Myasthenia Gravis Enrollment closed, study ongoing UCB Biopharma SRLPhase 4 NCT07246564
  13. Minor: ETNA · Povetacicept · Generalized Myasthenia Gravis Enrollment closed, study ongoing Vertex Pharmaceuticals IncorporatedPhase 2 NCT07501702
  14. Minor: Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis Trial completed First Affiliated Hospital of Chongqing Medical UniversityNot specified NCT06707727
  15. Minor: Claseprubart · Generalized Myasthenia Gravis (EMERGE) Trial sites expanded: 4 → 12 locations Dianthus TherapeuticsPhase 3 NCT07647510
  16. Notable: Anitocabtagene Autoleucel · Non-Oncology Plasma Cell-Related Diseases Primary and study completion dates pushed to Oct 2028 Kite, A Gilead CompanyPhase 1 NCT06626919
  17. Notable: SHR-2173 Injection · Myasthenia Gravis Recruitment opened Guangdong Hengrui Pharmaceutical Co., LtdPhase 2 NCT07622342
  18. Minor: Ravulizumab in Chinese Adults · Generalized Myasthenia Gravis (gMG) Start date pushed from Jul 20, 2026 to Jul 27, 2026 Alexion Pharmaceuticals, Inc.Phase 3 NCT07596784
  19. Notable: HERMOSA-2 · KITE-363 · Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment Primary endpoint(s) modified Kite, A Gilead CompanyPhase 1 NCT07304154
  20. Minor: 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study · Generalized Myasthenia Gravis Trial status changed: Enrolling by Invitation → Active, Not Recruiting UCB Biopharma SRLPhase 3 NCT06540144
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-14 NCT07818291 An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR… Shanghai Lanyi Therapeutics Co., Ltd. new Phase 1

Active trials by phase

Early Phase 1
9
Phase 1
17
Phase 1/2
8
Phase 2
12
Phase 2/3
9
Phase 3
26
Phase 4
7
Not charted: 70 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Top sponsors by active trials in this area

argenx (12) · Alexion Pharmaceuticals, Inc. (8) · UCB Biopharma SRL (6) · Centre Hospitalier Universitaire de Nice (5) · Tongji Hospital (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (4) · AstraZeneca (3) · Cartesian Therapeutics (3) · Daishi Tian (3) · Huashan Hospital (3)

Get alerts when Myasthenia Gravis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials